RAPP

Rapport Therapeutics, Inc. - Common Stock (RAPP)

About Rapport Therapeutics, Inc. - Common Stock (RAPP)

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Details

Daily high

$11.65

Daily low

$10.78

Price at open

$11.34

52 Week High

$29.74

52 Week Low

$6.43

Market cap

415.3M

Dividend yield

0.00%

Volume

77,755

Avg. volume

184,190

P/E ratio

-5.32

Rapport Therapeutics, Inc. - Common Stock News